PMID- 38230960
OWN - NLM
STAT- Publisher
LR  - 20240117
IS  - 1531-4995 (Electronic)
IS  - 0023-852X (Linking)
DP  - 2024 Jan 17
TI  - Real-World Outcomes of Inoperable and Metastatic Cutaneous Head and Neck Melanoma 
      Patients.
LID - 10.1002/lary.31290 [doi]
AB  - OBJECTIVE: This study aims to describe the overall survival (OS) and to identify 
      associated prognostic factors in patients with inoperable and metastatic 
      cutaneous melanoma of the head and neck (H&N) region, undergoing modern systemic 
      treatments. METHODS: This is a retrospective single institutional study. Data on 
      all consecutive H&N melanoma patients treated with systemic oncologic treatments 
      between 2015 and 2022 were collected from electronic medical files. Kaplan-Meier 
      curves were used to describe survival and Cox regression analysis was used to 
      identify patient and tumor factors associated with prognosis. RESULTS: A total of 
      144 patients were included. Median OS was 45 months (95% confidence interval [CI] 
      28-65 m). On univariable analysis for OS, the primary disease site, specifically 
      the nape and neck (hazard ratio [HR] 3.3, 95% CI 1.4-7.7, p = 0.007), high 
      Eastern Cooperative Oncology Group Performance Status ([ECOG-PS], HR 2.5, 95% 
      CI = 1.9-3.3, p < 0.001), high lactate dehydrogenase (LDH) levels (HR 2.8, 95% 
      CI = 1.7-4.6, p < 0.001), and treatment with targeted therapy (TT) as compared 
      with immunotherapy (HR 2.6, 95% CI = 1.06-6.3, p = 0.03) were all associated with 
      shorter OS. High-grade adverse events (AEs) were associated with a longer OS (HR 
      0.41, 95% CI = 0.25-0.68, p = 0.001). On multivariable analysis for OS, the 
      ECOG-PS, LDH levels, site of disease, and the development of moderate-severe AEs 
      remained significant. CONCLUSIONS: In the era of modern oncologic treatments, the 
      prognosis of inoperable and metastatic cutaneous H&N melanoma aligns with other 
      cutaneous melanomas. Primary tumor site of the nape and neck region emerges as a 
      significant prognostic factor. LEVEL OF EVIDENCE: 3 Laryngoscope, 2024.
CI  - (c) 2024 The American Laryngological, Rhinological and Otological Society, Inc.
FAU - Rozendorn, Noa
AU  - Rozendorn N
AUID- ORCID: 0000-0002-2912-2533
AD  - Department of Otolaryngology-Head and Neck Surgery, Sheba Medica Center, Ramat 
      Gan, Israel.
FAU - Shutan, Itay
AU  - Shutan I
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Feinmesser, Gilad
AU  - Feinmesser G
AD  - Department of Otolaryngology-Head and Neck Surgery, Sheba Medica Center, Ramat 
      Gan, Israel.
FAU - Grynberg, Shirly
AU  - Grynberg S
AD  - Ella Lemelbaum Institute of Immuno-Oncology, Sheba Medical Center, Ramat Gan, 
      Israel.
FAU - Hodadov, Hadas
AU  - Hodadov H
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Alon, Eran
AU  - Alon E
AD  - Department of Otolaryngology-Head and Neck Surgery, Sheba Medica Center, Ramat 
      Gan, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Asher, Nethanel
AU  - Asher N
AD  - Skin Cancer and Melanoma Center, Davidoff Center, Beilinson Medical Center, Petah 
      Tikva, Israel.
LA  - eng
PT  - Journal Article
DEP - 20240117
PL  - United States
TA  - Laryngoscope
JT  - The Laryngoscope
JID - 8607378
SB  - IM
OTO - NOTNLM
OT  - cutaneous melanoma
OT  - immunotherapy
OT  - real-world study
OT  - survival
OT  - targeted therapy
EDAT- 2024/01/17 12:43
MHDA- 2024/01/17 12:43
CRDT- 2024/01/17 09:12
PHST- 2023/12/26 00:00 [revised]
PHST- 2023/09/02 00:00 [received]
PHST- 2024/01/04 00:00 [accepted]
PHST- 2024/01/17 12:43 [medline]
PHST- 2024/01/17 12:43 [pubmed]
PHST- 2024/01/17 09:12 [entrez]
AID - 10.1002/lary.31290 [doi]
PST - aheadofprint
SO  - Laryngoscope. 2024 Jan 17. doi: 10.1002/lary.31290.